Clinical Guidelines

MENU

Cervical cancer screening

National Cervical Screening Program

Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding

GUIDELINE UPDATES - This guideline was last updated 1/27/2022

UPCOMING GUIDELINES - This guideline was updated and comes into practice on 7/1/2022Download PDF

Foreword

Introduction

Summary of recommendations

1. Cervical cancer in Australia

2. The rationale for primary HPV screening

3. Terminology

4. Unsatisfactory cervical screening results

5. Benefits, harms and cost-effectiveness of cervical screening

6. Management of oncogenic HPV test results

7. Colposcopy

8. Management of discordant colposcopic impression, histopathology and referral LBC prediction

9. Management of histologically confirmed low-grade squamous abnormalities

10. Management of histologically confirmed high-grade squamous abnormalities

11. Management of glandular abnormalities

12. Screening in Aboriginal and Torres Strait Islander women 

13. Screening after total hysterectomy

14. Screening in pregnancy

15. Screening in women who have experienced early sexual activity or have been victims of sexual abuse

16. Screening in immune-deficient women

17. Screening in DES-exposed women

18. Signs and symptoms of cervical cancer

19. Psychosocial care

20. Transition to the renewed National Cervical Screening Program

Appendices


Please see the Australian Department of Health Cancer Screening website for information about the National Cervical Screening Program (NCSP) and policies on transitioning women to the renewed NCSP.

Resources

Cervical cancer screening online education modules (e-learning)



Endorsed by 

Cancer Council would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.
Acknowledgement Image Title
Cancer Council Australia